- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06225232
Psilocybin in the Treatment of Cannabis Use Disorder: A-Proof-of-Concept Study (PSI_CUD)
January 17, 2024 updated by: McMaster University
A 9-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study
Cannabis is the most commonly used psychoactive substance in Canada (Lowry & Corsi, 2020).
A sub-group of cannabis users develop a condition known as Cannabis Use Disorder (CUD), which is defined as a regular pattern of cannabis use that causes performance difficulty at work, school and relationships (Hasin et al., 2013).
A review of current treatments available for CUD indicate the lack of a pharmacological and psychological treatment with high success rates, which highlights the importance of exploring potential psychosocial interventions for the treatment of CUD.
Given the evidence of psilocybin's therapeutic potential in the treatment of substance use disorders (de Veen et al., 2017), we aim to conduct a study using psilocybin-assisted-psychotherapy in the treatment of CUD.
The study aims to evaluate the feasibility, safety, tolerability and potential therapeutic effect of 2 doses [25 mg] of psilocybin administered as part of a 9-week Motivational Enhancement Therapy (MET) and supportive therapy.
This trial will be the first to evaluate the potential treatment effects of psilocybin on symptoms of CUD.
Study Overview
Status
Not yet recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
16
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Beth Patterson
- Phone Number: 905-921-7644
- Email: bpatter@mcmaster.ca
Study Contact Backup
- Name: Maryam Rahat
- Phone Number: 905-921-7644
- Email: rahatvam@McMaster.ca
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed Informed Consent Form.
- Able to show documentation of identity.
- Fluent in speaking and reading English and able to complete rating scales and assessments.
- Between the ages of 18 to 65.
- At Screening, meet criteria for CUD diagnosis of at least moderate severity as per the MINI Plus
- Expressed a wish to reduce or stop cannabis use.
- Medically healthy based on physician review of CBC, electrolytes, liver function test, kidney function tests and ECG.
- Has a stable residence for the duration of the study.
- Agree to comply with the protocol requirements set out by the study.
- Consent to providing regular check-ins and follow-up regarding any medical conditions, procedures and adverse events.
- If of child-bearing potential, female participants must agree to use an adequate birth control method (IUD, injected or implanted hormonal methods, abstinence, vasectomy of the partner/partners, or double barrier contraception i.e. condoms plus diaphragm, or diaphragm plus spermicide) for the duration of the study. Male participants should agree to using condoms with spermicide throughout the trial in addition to the use of an adequate contraceptive by their partner of childbearing potential.
- Following discharge from the dosing sessions, agree to have another individual accompany them home from the study site and stay with them overnight.
Exclusion Criteria:
- Meet DSM-5 criteria for lifetime history of bipolar disorder, schizophrenia, or other psychotic disorders, personality disorders, delirium, dementia and amnesic and other cognitive disorders, or are in a current agitated state.
- Have first-degree biological relatives (parents or full siblings) with past or present history of schizophrenia, bipolar disorder and any other psychosis.
- Meet DSM-5 criteria for panic disorder or seizure disorders.
- Meet DSM-5 criteria for dependence of any substance other than cannabis or tobacco in the past 6 months.
- Positive urine drug screen for substances tested with the exception of cannabis
- Lifetime history of serotonergic psychedelic use (psilocybin, LSD, Ayahuasca, mescaline, DMT).
- Current treatment with psychotropic agents including stimulants, anti-psychotic agents, benzodiazepines and tri-cyclic anti-depressants. Concurrent treatment with Selective Serotonin Reuptake Inhibitors and Serotonin Noradrenalin Reuptake Inhibitors will be allowed, provided the dose has been stable for 4 weeks and remains stable during the study.
- History of cardiovascular diseases or uncontrolled hypertension that is not successfully treated or any other medical condition that might pose a risk to the participant in the opinion of the study physician.
- Are receiving concurrent psychotherapy for CUD.
- Are reasonably judged to present a serious suicide risk as determined by Columbia Suicide Severity Rating Scale or expressed homicide risk, who have enacted suicidal behaviors within 6 months prior to intake, or w ho are likely to require psychiatric hospitalization during the study.
- Participants of childbearing potential with a positive pregnancy test at screening or prior to dosing sessions, or are pregnant, breast feeding, and who are not using an acceptable means of birth control for the duration of the study.
- Are unable to fully understand the potential risks and benefits of the study and give informed consent.
- Are currently or planning on participating in other interventional clinical trials during this study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
This is an open-label single arm intervention trial.
Participants in this arm will be offered both drug and psychotherapy as part of their 9-week intervention.
|
The intervention consists of a 9-week treatment protocol that is based on supportive psychotherapy and Motivational Enhancement Therapy.
Overall, the therapy course includes 8 motivational enhancement therapy sessions and two experimental drug sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of spontaneously reported adverse events and serious adverse events from baseline to the nine-week endpoint
Time Frame: 9 weeks
|
frequency, type and severity of outcomes are recorded
|
9 weeks
|
Percent of recruited participants who discontinue or are lost to follow up before completing the 9-ween treatment protocol
Time Frame: 9 weeks
|
frequency of cases of withdrawal and lost to follow up are documented and a percent is calculated based on the total number of participants recruited in this study.
|
9 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility measured by number of individuals who express interest by contacting the study team, percent of individuals who are screened as eligible to those who contact the study, percent of those who complete the trial to those who are enrolled
Time Frame: 9 weeks
|
Reported in frequency and percentages
|
9 weeks
|
Efficacy a: frequency and amount of cannabis use, as measured by the Timeline Follow Back from baseline to the nine-week end point
Time Frame: 9 weeks
|
This is measured using the Timeline Follow Back tool
|
9 weeks
|
Efficacy b: Severity of symptoms associated with Cannabis Use Disorder as measured by Self-Reported Symptoms of Cannabis Use Disorder from baseline to 9 week endpoint
Time Frame: 9 weeks
|
Self-Reported Symptoms of Cannabis Use Disorder
|
9 weeks
|
Efficacy c: Changes in Urinary Cannabinoids from baseline to the nine-week endpoint
Time Frame: 9 weeks
|
Urinary Cannabinoid Test
|
9 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
severity of symptoms of craving, withdrawal, anxiety, depression and functional impairment
Time Frame: 9 weeks
|
Measured using Marijuana Withdrawal Checklist, Marijuana Craving Questionnaire, Patient Health Questionnaire - 9, Generalized Anxiety Disorder, Sheehan Disability Scale
|
9 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
March 1, 2024
Primary Completion (Estimated)
March 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
January 4, 2024
First Submitted That Met QC Criteria
January 17, 2024
First Posted (Estimated)
January 25, 2024
Study Record Updates
Last Update Posted (Estimated)
January 25, 2024
Last Update Submitted That Met QC Criteria
January 17, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PSI_CUD
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use Disorder, Moderate
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Assiut UniversityUnknownCannabis Use Disorder, Moderate
-
Ellen HerbstTobacco Related Disease Research ProgramRecruitingTobacco Use Disorder | Cannabis Use | Drug Use DisorderUnited States
-
VA Office of Research and DevelopmentRecruitingTobacco Use Disorder | Cannabis Use DisorderUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Dartmouth-Hitchcock Medical CenterNational Institute on Drug Abuse (NIDA)Completed
Clinical Trials on Psilocybin combined with Psychotherapy
-
Beersheva Mental Health CenterNot yet recruitingObsessive-compulsive Disorder
-
Oslo University HospitalSouth-Eastern Norway Regional Health AuthorityUnknown
-
University of OtagoEnrolling by invitationDepressive Disorder, Treatment-ResistantNew Zealand
-
University of WashingtonActive, not recruitingDepression | COVID-19 | Burnout, Professional | Post Traumatic Stress Disorder | Burnout, Caregiver | Moral InjuryUnited States
-
University of British ColumbiaEtheridge FoundationNot yet recruitingChronic Pain | Opioid DependenceCanada
-
Yvan Beaussant, MD, MSciHeffter Research Institute; Usona Institute; Oppenheimer Family Psychosocial... and other collaboratorsActive, not recruitingTerminal Illness | Psychotherapy | Psilocybin | Hospice | Demoralization | Cancer-related Problem/Condition | Terminal Cancer | Cancer TerminalUnited States
-
Marianne Lau, MD, DSci.The Ministry of Science, Technology and Innovation, DenmarkUnknownBulimia Nervosa (BN) | Binge Eating Disorder (BED) | Eating Disorder Not Otherwise Specified (EDNOS)Denmark
-
Universidad de CórdobaMinisterio de Economía y Competitividad, SpainCompletedDepression | Anxiety Disorders | Somatoform Disorders | Common Mental DisordersSpain
-
University of IowaNational Institute of Mental Health (NIMH)CompletedDepression | Heart Failure | Chronic Obstructive Pulmonary DiseaseUnited States
-
Kevin BoehnkeRecruiting